Summary

Kyle Guse is a partner with Baker Botts and is based in the firm’s Palo Alto office. Kyle focuses his practice on corporate counseling, mergers and acquisitions, public offerings, private financings and other corporate matters. He has completed in excess of 100 public offerings and M&A transactions with many innovative and fast growing life sciences and technology companies. His clients primarily include public and private companies, venture capital funds and investment banks in the life sciences, technology and clean-tech sectors. Kyle has a particular emphasis counseling rapidly growing companies through public offerings and mergers and acquisitions. He is a former certified public accountant having worked at a Big 4 accounting firm.

Kyle has been identified by The Legal 500 as one of the leading lawyers in his field.

Representative Engagements

• Numerous initial public offerings and follow-on offerings for life science companies, including Advanced BioHealing, Inc. (converted to M&A), Apricus Bio and DepoMed, Inc., and their investment banks including BofA Merrill Lynch and Dawson James Securities.
• Securities offering for Quantum Fuel Systems Technologies Worldwide, Inc., the sole supplier of drive trains and controllers to Fisker Automotive Inc.
• Public spin-out and general corporate matters for Catalytic Energy Systems, Inc.
• Multiple securities offerings, merger and acquisition transactions and outside general corporate counsel for Secure Computing Corporation, a leading internet security company acquired by McAfee, Inc.
• Initial public offering, follow-on public offering, multiple acquisitions, general corporate counseling and disposition for REMEC, Inc., a microwave manufacturer for the U.S. government and private sector.
• Significant transactions for companies with DARPA and DOE grants, including Oxonica Materials, Inc. and Nova Research, Inc.
• Acquisition and subsequent disposition of Oxonica Materials, Inc., a nanotechnology materials company, to Cabot Corporation, a leading chemicals company.
• Initial public offering, follow-on offering and multiple acquisitions for Maxygen, Inc., a biotechnology company using molecular breeding to develop and commercialize products for the chemical and pharmaceutical industries.
• Multiple public offerings, mergers and acquisitions and general corporate counseling for Thoratec Corporation and Angiotech Pharmaceuticals, Inc., including one of the largest cross-border public offerings of the year.
• 100+ venture capital financing transactions and IPOs for companies backed by virtually all the leading VC firms, including 3i, ABN-AMRO, Alta Partners, Alter Tech Ventures, Baker Brothers, Bessemer Venture Partners, General Electric Capital Corporation, Institutional Venture Partners, Invemed Associates, KPG Venture Partners, Lightspeed Venture Partners, Morgenthaler Partners, NEA, New Leaf Ventures, Pequot Capital Management, Sofinnova Ventures, Sutter Hill Ventures, Technogen Associates, Three Arch Partners and Warburg Pincus.
• Merger and acquisition transactions involving many of the leading technology companies, including Agilent Technologies, Inc., Computer Associates, Inc., IBM, Sony Corporation of America, Symantec, Inc., McAfee, Inc., L-1 Identity Solutions, Inc., Secure Computing Corporation and Sum Total Systems, Inc.